Disease Area: Bowel Diseases

Preventis® SmarTest® FIT Home test is a quantitative home test system for measuring hidden (occult) traces of blood in stool samples. This in vitro diagnostic device (IVD) is intended for self-testing to support screening for colorectal cancer and adenomatous polyps in patients who may benefit from further investigations.

Determination of free therapeutic certolizumab

Certolizumab is the Fab’ fragment of a recombinant humanised antibody conjugated to polyethylene glycol (PEG) and is therefore also known as “certolizumab pegol”. The IDKmonitor Certolizumab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free certolizumab therapeutic drug in serum and EDTA plasma samples.

Preventis SmarTest Calprotectin Home test is a quantitative home test system for measuring calprotectin in stool samples. This in vitro diagnostic device (IVD) is intended for self-testing and individual monitoring of disease activity and treatment efficacy for patients with chronic inflammatory bowel disease (IBD).

The GA-Map Dysbiosis test is the first clinical test that identifies and characterises dysbiosis based on faecal specimens. It does this by exploiting single nucleotide differences in the 16S rRNA gene – a gene that is common to all bacteria. With 48 highly specific probes, the GA-map Dysbiosis Test identifies over 300 species of bacteria using cutting edge high throughput technology.

Stool samples can be extracted directly and efficiently using the IDK Stool Sample Application System, which allows easy, clean and precise preparation of sample extracts.

Stool samples can be extracted directly and efficiently using the IDK Stool Sample Application System, which allows easy, clean and precise preparation of stool sample extracts.

Stool samples can be extracted directly and efficiently using the IDK TurbiTUBE, which allows easy, clean and precise preparation of sample extracts.

Ustekinumab is a fully humanised IgG1 therapeutic monoclonal antibody used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. This assay enables the reliable determination of free, unbound anti-drug antibodies.

Ustekinumab is a fully humanised IgG1 therapeutic monoclonal antibody used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. This drug-tolerant assay enables the reliable determination of anti-drug antibodies even in the presence of ustekinumab.

BIOHIT Faecal Calprotectin Extraction Tubes are intended for the extraction of human stool samples for measurement of calprotectin using the BIOHIT Calprotectin ELISA.

The IDK TurbiFIT employs a particle-enhanced turbidimetric immunoassay (PETIA) methodology, utilising polyclonal antibodies to accurately quantify human haemoglobin levels in stool samples.

The IDK TurbiCAL is a particle enhanced turbidimetric immunoassay (PETIA) that uses monoclonal antibodies for the determination of human calprotectin (MRP 8/14; S100A8/A9) in stool samples.

PreventID CalDetect 50/200 is a rapid immunochemical test that semi-quantitatively screens and measures calprotectin in stool samples in just 10 minutes. Faecal calprotectin is an exceptionally accurate and convenient marker for investigating bowel inflammation in patients presenting with abdominal symptoms, or monitoring those with inflammatory bowel disease (IBD).

Preventis SmarTest Pro Vitamin D is a rapid test system for the quantitative determination of 25(OH) vitamin D in finger-prick blood samples, ideal for GPs, pharmacies and outpatient clinics. This quantitative test supports fast and effective vitamin D supplement optimisation, and enables close monitoring of 25(OH) vitamin D levels in a point of care setting. The kit contains everything needed to prepare, collect and test a finger-prick blood sample in combination with the SmarTest Vitamin D app.

The CE-marked GA-map COVID-19 Fecal Test is designed to qualitatively detect SARS-CoV-2 RNA in faecal samples. This kit is suitable for patients exhibiting symptoms of COVID-19 (confirmation and management), as well as those in the recovery phase (surveillance and clearance), asymptomatic individuals concerned about possessing and transmitting the virus (prevention), and for screening faecal microbiota transplant (FMT) donors.

BIOHIT ColonView Hb and Hb/Hp test can be used to screen for lower gastrointestinal (GI) organic pathologies, such as colorectal cancers and large adenomas that bleed. ColonView is a new generation lateral flow faecal immunochemical test (FIT), intended for the rapid detection of faecal occult blood (FOB) in stool samples.

The BIOHIT Total 25OH Vitamin D ELISA is a quantitative immunoenzymatic assay for the determination of 25-hydroxyvitamins D2 and D3 (25OHD2 and 25OHD3) in serum and plasma, to aid in the diagnosis of vitamin D deficiency, insufficiency or intoxication.

The BIOHIT Calprotectin ELISA is a quantitative sandwich ELISA method for the detection of calprotectin in stool samples. It can be used to help identify organic diseases of the small or large intestine, and to monitor disease activity and response to treatment in patients with ulcerative colitis or Crohn’s disease.

The BIOHIT Celiac Quick Test is a rapid immunochromatographic test for the qualitative detection of antibodies (IgA, IgG, IgM) against human tissue transglutaminase (tTG2A) in capillary whole blood samples.

The BIOHIT Lactose Intolerance Quick Test supports the diagnosis of lactose intolerance (hypolactasia of the small intestine) by detecting lactase enzyme activity in a duodenal biopsy specimen.

The IDK Zonulin (Stool) ELISA is a quantitative assay designed for the precise determination of zonulin levels in stool samples. Zonulin, a protein intricately involved in intestinal barrier function, has garnered attention as a potential marker for the phenomenon commonly known as “leaky gut” syndrome.

The IDK Zonulin (Serum) ELISA is a quantitative assay for the determination of zonulin in serum. Zonulin is a protein that is involved in intestinal barrier function, and has been highlighted as a potential marker of so called “leaky gut” syndrome.

The IDK Lactoferrin ELISA is an enzyme immunoassay for the quantitative determination of lactoferrin – a well-established biomarker for neutrophilic intestinal inflammation – in stool samples. Faecal lactoferrin measurement supports monitoring of disease activity in inflammatory bowel disease (IBD), prediction of relapse of IBD and assessment of treatment response in IBD.

The IDK Faecal Calprotectin ELISA is an enzyme immunoassay for the quantitative determination of human calprotectin (MRP 8/14; S100A8/A9) in stool samples, to rule out and monitor inflammatory bowel diseases (IBDs) non-invasively.

The innovative IDK Faecal Bile Acids assay allows quantitative determination of bile acids in stool samples. This rapid photometric assay can aid the diagnosis of bile acid diarrhoea in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS) or can be used to support differential diagnosis of bile acid malabsorption.

The IDK Faecal Haemoglobin ELISA stands as a cutting-edge enzyme immunoassay designed to deliver precise quantitative measurements of human haemoglobin in stool samples. This assay serves as a crucial marker for identifying early colorectal cancer and adenomatous polyps by detecting gastrointestinal bleeding, particularly originating from colorectal adenomas and tumours.

The IDKmonitor Vedolizumab Free Anti-drug ELISA kit is a microplate-based quantitative sandwich ELISA for the determination of free anti-vedolizumab antibodies in plasma or serum samples. Detecting high levels of free anti-vedolizumab antibodies in patients when the drug level is low (undetectable or sub-therapeutic) may indicate poorer long-term outcomes and suggest the need to switch treatment.

Vedolizumab is a recombinant protein used to treat Crohn’s disease and ulcerative colitis. The IDKmonitor Vedolizumab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free vedolizumab in plasma or serum samples.

Ustekinumab is a recombinant protein used to treat inflammatory bowel disease (IBD). The IDKmonitor Ustekinumab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free ustekinumab in plasma or serum samples.

Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response. The IDKmonitor Infliximab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating drug.

Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). The IDKmonitor Infliximab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free infliximab in plasma or serum samples.

Golimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). The IDKmonitor Golimumab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free golimumab in plasma or serum samples.

Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response. The IDKmonitor Adalimumab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating drug.

Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). The IDKmonitor Adalimumab Drug Level ELISA kit is a microplate-based quantitative sandwich ELISA for the determination of free therapeutic TNFα antibodies (adalimumab) from plasma or serum samples.

Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation which is a major cause of loss of drug response.

Golimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response.

Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response.

The IDK Oncostatin M (OSM) ELISA is used for the quantitative determination of oncostatin M in serum, plasma or stools. OSM and its receptor, OSMR, are involved in gut inflammation, and are upregulated in the mucosa of IBD patients.